Current Clinical Trials

Answer ALS

Participants: Persons with ALS.

Background: The purpose of this research study is to create a large repository of cells called induced pluripotent stem cells (iPSCs), bio-fluid samples (blood and spinal fluid (optional), and cell lines for ALS gene identification. This will be combined carefully with collected measures of the pattern of the symptoms people with ALS have and how these change over time.

What takes place in the study: 5 study visits to include the following: blood draws, muscle strength testing (HHD), questionnaires and breathing test. There is also an optional lumbar puncture.

View study flier

Contact Information:
neuroclinicalstudies@neuro.wustl.edu
314-362-6159

SOD1 Half-life Measurements in SOD1 Positive ALS Patients

Participants: Persons with ALS and healthy controls.

Background: Understanding the half-life of the SOD1 protein in cerebral spinal fluid in both ALS and controls will help us in planning clinical trials for ALS patients with SOD1 mutations.

What takes place in study: 10-day controlled diet, blood draws and 4 lumbar puncture procedures to obtain CSF.

View study flier

Contact Information:
neuroclinicalstudies@neuro.wustl.edu
314-362-6159

Understanding C9ORF72 Related ALS

New! View the Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium Educational Webinar featuring this study.

Participants: People with a genetic form of ALS caused by a mutation in C9ORF72

Background: For some people, their ALS is caused by a mutation in the DNA. We are interested in better understanding ALS in the subset of ALS patients that have a mutation in the gene C9ORF72.

What takes place in study: Recording of clinical measures associated with ALS, for example measures of breathing and blood draws. All of this can take place during the normal clinic visit. Though not mandatory, undergoing a lumbar puncture to obtain cerebral spinal fluid (CSF) is encouraged.

View study flier

Contact Information:
neuroclinicalstudies@neuro.wustl.edu
314-362-6159

Cross-Sectional ALS Biofluid Study (CABB)

Participants: Persons with ALS, PLS, or PMA diagnosed by a neurologist; asymptomatic ALS gene carriers; and a comparison/control group (do not have ALS, PLS, PMA, or a gene known to cause ALS. These people may have other neurological diseases, such as Kennedy’s Disease or Paralytic Polio.)

Background: The purpose of the study is to extend and enlarge a biofluid repository of blood, plasma, serum, DNA, urine, and cerebrospinal fluid (CSF) collected from people with ALS and control participants to support research and identify biomarkers of ALS and other diseases. The eventual goal is to enroll a total of up to 1,000 study participants.

Recent advances in biomarker discovery in Alzheimer’s disease were based on precisely such a large-scale biofluid repository. Once specific ALS biomarkers have been discovered, these could be used to make earlier diagnoses, monitor disease progression, design new therapies, or test drug efficacy in clinical trials.

What takes place in study: After the initial visit, optional follow-up visits will occur at approximately 6 month intervals for one year. Recording of clinical measures associated with ALS, for example, measures of breathing and blood draws, will occur. All of this can take place during the normal clinic cisit. Though not mandatory, undergoing a lumbar puncture to obtain CSF is encouraged.

Contact Information:
neuroclinicalstudies@neuro.wustl.edu
314-362-6159

ALS Methodology Study

Participants: Persons with ALS.

Background: This study looks at new methods to evaluate ALS symptoms over time to see if these new approaches are better at detecting changes than the currently used methods. The methods for measuring ALS symptoms that will be used in this study include electrophysiological tests, muscle strength tests, lung function tests and questionnaires about your ALS status.

View study flier

Contact Information:
neuroclinicalstudies@neuro.wustl.edu
314-362-6159

Genomic Translation of the ALS Clinical Care (GTAC)

Participants: Persons with ALS (defined by EEC), primary lateral sclerosis (PLS), and progressive muscular atrophy.

Background: Across the United States and Scotland, this study will enroll and actively follow 1500 ALS patients with current clinic contact. This rich, clinical dataset will be paired with the analysis of collected blood samples (e.g. DNA) to clarify the complex effects large networks of genes have on the risk and clinical course of ALS. This project will link clinical, treatment, and outcome information to genetics in order to better understand the underlying manner of ALS development. The resulting dataset will be made openly and freely available to other researchers.

Contact Information:
neuroclinicalstudies@neuro.wustl.edu
314-362-6159

Evaluation of Biomarkers in Blood

Participants: People with neuromuscular diseases OR normal healthy controls.

Background: Understanding the changes in blood that occur during disease helps us better understand the disease and better design new therapies. These changes that occur during disease are often called “biomarkers” in that they mark or identify or are associated with the disease. To understand changes during disease, we also need to understand normal or “controls” without the disease.

What takes place in study: Serial blood draws at each clinic visit (or scheduled through an outside clinic or at-home visit)

View study flier

Contact Information:
neuroclinicalstudies@neuro.wustl.edu
314-362-6159

Cerebrospinal Fluid Biorepository

Participants: Healthy volunteers and those diagnosed with a disease of the nerve, muscle or brain. Participants must be 45 to 75 years old, must have a BMI of less than or equal to 35, must not have a bleeding disorder, and must not be taking blood thinners.

Background: Cerebrospinal fluid (CSF) is a clear liquid which bathes the brain and spine. Our researchers gather, bank and study the CSF of individuals with neurodegenerative disorders and healthy volunteers. The CSF provides a valuable comparison which helps us to understand, diagnose and treat neurologic diseases.

What takes place in study: Participation will take approximately 3 hours. There will be about 2 or 3 study visits. There will be a physical exam, spinal tap, and 2 blood draws. Risks will be discussed with volunteers as part of the informed consent process. Participants will receive $200 for completing all parts of the study.

New! Patients with sporadic ALS are needed for this study. 

View study flier for healthy controls

Contact Information:
neuroclinicalstudies@neuro.wustl.edu
314-362-6159